Updates on Anti-Cancer Therapy in Ovarian Cancer
- *Corresponding Author:
- Dana M Chase
The Division of Gynecologic Oncology
University of Arizona Cancer Center
Creighton University School of Medicine
St. Joseph's Hospital and Medical Center, Phoenix, USA
E-mail: [email protected]
Received date: February 07, 2013; Accepted date: March 26, 2013; Published date: March 28, 2013
Citation: Chase DM, Gibson SJ, Monk BJ, Tewari KS (2013) Updates on Anti-Cancer Therapy in Ovarian Cancer. Chemotherapy 2:109. doi: 10.4172/2167-7700.100109
Copyright: © 2013 Chase DM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Drug discovery in the ovarian cancer arena continues to launch important new clinical trials. Many biologic agents are being studied in phase II and phase III clinical trials for recurrent disease. These agents include compounds that disrupt angiogenesis through a variety of mechanisms. Other oncogenic pathways are also specifically targeted with investigational PARP, HDAC, MEK, topoisomerase and COX-2 inhibitors currently being studied. Various cytotoxic agents, as well as therapeutic vaccines, are also under investigation, and continue to demonstrate promising new data. The relevant agents in the treatment of ovarian cancer which have demonstrated positive phase II activity, will be discussed.